Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.
chemotherapy
human epidermal growth factor receptor 2-positive
invasive breast carcinoma
monoclonal antibody
neoadjuvant and adjuvant treatment
pertuzumab
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Aug 2023
30 Aug 2023
Historique:
received:
08
06
2023
revised:
08
08
2023
accepted:
16
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15-20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant approach has multiple benefits that include the potential to downgrade staging and convert previously unresectable tumors to operable tumors. In addition, achieving a pathologic complete response (pCR) following preoperative systemic treatment is prognostic of enhanced survival outcomes. Thus, optimal evaluation among the suitable strategies is crucial in deciding which patients should be selected for the neoadjuvant approach. A literature search was conducted in the Embase, Medline, and Cochrane electronic libraries. The evaluation of tumor and LN staging and, hence, stratifying BC recurrence risk are decisive factors in guiding clinicians to optimize treatment decisions between the neoadjuvant versus adjuvant approaches. For each individual case, it is important to consider the most likely postsurgical outcome, since, if the patient does not obtain pCR following neoadjuvant treatment, they are eligible for adjuvant T-DM1 in the case of residual disease. This review of HER2-positive female BC outlines suitable neoadjuvant and adjuvant systemic treatment strategies for guiding clinical decision making around the selection of an appropriate therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15-20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant approach has multiple benefits that include the potential to downgrade staging and convert previously unresectable tumors to operable tumors. In addition, achieving a pathologic complete response (pCR) following preoperative systemic treatment is prognostic of enhanced survival outcomes. Thus, optimal evaluation among the suitable strategies is crucial in deciding which patients should be selected for the neoadjuvant approach.
METHODS
METHODS
A literature search was conducted in the Embase, Medline, and Cochrane electronic libraries.
CONCLUSION
CONCLUSIONS
The evaluation of tumor and LN staging and, hence, stratifying BC recurrence risk are decisive factors in guiding clinicians to optimize treatment decisions between the neoadjuvant versus adjuvant approaches. For each individual case, it is important to consider the most likely postsurgical outcome, since, if the patient does not obtain pCR following neoadjuvant treatment, they are eligible for adjuvant T-DM1 in the case of residual disease. This review of HER2-positive female BC outlines suitable neoadjuvant and adjuvant systemic treatment strategies for guiding clinical decision making around the selection of an appropriate therapy.
Identifiants
pubmed: 37686612
pii: cancers15174336
doi: 10.3390/cancers15174336
pmc: PMC10486709
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
EBioMedicine. 2022 Jan;75:103801
pubmed: 34990895
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
Curr Stem Cell Rep. 2018;4(1):81-94
pubmed: 29600163
J Clin Oncol. 2019 Aug 1;37(22):1868-1875
pubmed: 30939096
BMC Med. 2022 Dec 27;20(1):498
pubmed: 36575513
Lancet Oncol. 2021 Jun;22(6):858-871
pubmed: 34019819
J Clin Oncol. 2021 Jul 20;39(21):2375-2385
pubmed: 34077270
Lancet Oncol. 2018 Jan;19(1):115-126
pubmed: 29175149
Lancet Oncol. 2019 Mar;20(3):371-382
pubmed: 30765258
JAMA Oncol. 2018 Sep 1;4(9):1214-1220
pubmed: 29955792
Cancer Gene Ther. 2023 Jun;30(6):803-811
pubmed: 36765179
J Clin Oncol. 2014 Jul 10;32(20):2151-8
pubmed: 24888815
J Clin Oncol. 2019 Dec 10;37(35):3425-3435
pubmed: 31622131
Ann Oncol. 2021 Aug;32(8):1005-1014
pubmed: 33932503
Cancer Res. 2016 Jul 1;76(13):3702-10
pubmed: 27197192
Lancet. 2023 Jan 14;401(10371):105-117
pubmed: 36495879
Cancers (Basel). 2020 Jul 28;12(8):
pubmed: 32731409
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
Ann Oncol. 2006 Mar;17(3):409-14
pubmed: 16332965
J Clin Oncol. 2021 Feb 20;39(6):685-693
pubmed: 33079579
Breast Cancer Res Treat. 2021 Jun;187(3):903-913
pubmed: 33649981
Breast Cancer Res Treat. 2019 Aug;177(1):103-114
pubmed: 31134488
Breast Cancer. 2020 Jul;27(4):631-641
pubmed: 32060785
JAMA Oncol. 2023 Feb 1;9(2):197-205
pubmed: 36454580
J Clin Oncol. 2005 Jun 1;23(16):3676-85
pubmed: 15738535
Lancet Oncol. 2021 Aug;22(8):1139-1150
pubmed: 34339645
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
J Clin Oncol. 2019 Sep 1;37(25):2206-2216
pubmed: 31157583
Front Oncol. 2021 Jul 23;11:632357
pubmed: 34367947
J Clin Oncol. 2022 Jun 1;40(16):1816-1837
pubmed: 35439025
J Clin Oncol. 2007 Jul 1;25(19):2678-84
pubmed: 17515572
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Oncogene. 2007 Oct 4;26(45):6469-87
pubmed: 17471238
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
pubmed: 20730488
BMC Surg. 2021 Mar 23;21(1):160
pubmed: 33757489
Clin Med Insights Oncol. 2012;6:179-87
pubmed: 22518088
Tumour Biol. 2012 Oct;33(5):1349-62
pubmed: 22492237
Curr Oncol. 2023 May 16;30(5):5047-5049
pubmed: 37232838
J Clin Oncol. 2014 Jul 10;32(20):2142-50
pubmed: 24888816
Ann Oncol. 2015 Jul;26(7):1333-40
pubmed: 25935793
Ann Transl Med. 2023 Mar 15;11(5):200
pubmed: 37007556
Cancer Res. 2008 Jul 15;68(14):5878-87
pubmed: 18632642
J Clin Oncol. 2015 Aug 20;33(24):2600-8
pubmed: 26101239
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
NPJ Breast Cancer. 2022 Nov 30;8(1):127
pubmed: 36450763
Ann Oncol. 2022 Mar;33(3):321-329
pubmed: 34954044
Syst Rev. 2017 Oct 10;6(1):196
pubmed: 29017563
N Engl J Med. 2012 Jan 12;366(2):176-8
pubmed: 22149874
Cancer Treat Rev. 2022 Jan;102:102323
pubmed: 34896969
Eur J Med Chem. 2023 Jan 15;246:114971
pubmed: 36462440
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Crit Rev Oncol Hematol. 2018 Aug;128:130-138
pubmed: 29730143
Future Oncol. 2022 Jun;18(19):2339-2349
pubmed: 35465733
NPJ Breast Cancer. 2019 Jan 4;5:1
pubmed: 30675511
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
Future Oncol. 2022 Oct;18(32):3563-3572
pubmed: 36382554
Clin Cancer Res. 2020 Sep 1;26(17):4670-4681
pubmed: 32732224
Cancer Med. 2019 Mar;8(3):1258-1268
pubmed: 30701699
Front Immunol. 2022 Jun 03;13:913215
pubmed: 35720368
Eur J Cancer. 2023 May;184:48-59
pubmed: 36898233
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Biotechnol Lett. 2023 Mar;45(3):371-385
pubmed: 36650341
Hum Pathol. 2023 Jul;137:94-101
pubmed: 37094656
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
N Engl J Med. 2015 Jan 8;372(2):134-41
pubmed: 25564897
Mol Biotechnol. 2020 Jan;62(1):18-30
pubmed: 31691197
Lancet Oncol. 2021 Mar;22(3):351-360
pubmed: 33581774
Breast. 2020 Dec;54:203-210
pubmed: 33130486
Lancet Oncol. 2023 Mar;24(3):273-285
pubmed: 36858723
Eur J Cancer. 2018 Jan;89:27-35
pubmed: 29223479
Lancet. 2013 Sep 21;382(9897):1021-8
pubmed: 23871490
Cancers (Basel). 2019 May 28;11(6):
pubmed: 31141894
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Lancet. 2019 Jun 29;393(10191):2599-2612
pubmed: 31178152
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
Breast Cancer Res Treat. 2022 May;193(1):1-20
pubmed: 35224713
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Eur J Cancer. 2021 Oct 19;158:169-180
pubmed: 34678678
Int J Mol Sci. 2020 Dec 26;22(1):
pubmed: 33375317
J Clin Oncol. 1998 Aug;16(8):2659-71
pubmed: 9704716
Front Immunol. 2017 Nov 13;8:1554
pubmed: 29181010
Virchows Arch. 2022 Apr;480(4):749-758
pubmed: 35138452
JAMA Oncol. 2023 Jan 1;9(1):71-78
pubmed: 36326756
Ann Oncol. 2017 Apr 1;28(4):855-861
pubmed: 28119295
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Clin Cancer Res. 2019 May 1;25(9):2725-2736
pubmed: 30635338
J Clin Oncol. 2023 Jan 10;41(2):198-205
pubmed: 36332179
Breast Care (Basel). 2022 Feb;17(1):63-70
pubmed: 35355696
Cell Signal. 2022 Sep;97:110401
pubmed: 35820544
Future Oncol. 2021 Dec;17(34):4665-4676
pubmed: 34636255
J Hematol Oncol. 2019 Oct 29;12(1):111
pubmed: 31665051
Eur J Cancer. 2019 Sep;118:169-177
pubmed: 31377477
Ann Oncol. 2010 Oct;21 Suppl 7:vii36-40
pubmed: 20943641
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Cancer Treat Rev. 2019 May;75:12-19
pubmed: 30856373
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Lancet Oncol. 2013 Jul;14(8):741-8
pubmed: 23764181
J Clin Oncol. 2014 Nov 20;32(33):3753-61
pubmed: 25332247
Cancer Res. 2009 Dec 15;69(24):9330-6
pubmed: 19934333
Breast. 2022 Dec;66:97-109
pubmed: 36219945
J Clin Oncol. 2022 Feb 10;40(5):438-448
pubmed: 34890214
BJS Open. 2022 May 2;6(3):
pubmed: 35512244
Am Soc Clin Oncol Educ Book. 2018 May 23;38:457-467
pubmed: 30231399
Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188847
pubmed: 36516931
J Clin Oncol. 2022 Feb 10;40(5):449-458
pubmed: 34995105
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
JAMA Oncol. 2023 Jun 1;9(6):835-840
pubmed: 37103927
Curr Oncol. 2022 Jul 13;29(7):4956-4969
pubmed: 35877254
Lancet. 2019 Jun 29;393(10191):2591-2598
pubmed: 31178155
NPJ Breast Cancer. 2022 May 10;8(1):63
pubmed: 35538105
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
ESMO Open. 2022 Apr;7(2):100433
pubmed: 35276440
Lancet Oncol. 2021 Jun;22(6):779-789
pubmed: 33961795
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
Lancet Oncol. 2018 Dec;19(12):1630-1640
pubmed: 30413379
J Clin Oncol. 2021 Jan 10;39(2):126-135
pubmed: 33108242
Cancers (Basel). 2022 Jun 18;14(12):
pubmed: 35740668
J Clin Oncol. 2020 Dec 1;38(34):4120-4129
pubmed: 33052755
Clin Cancer Res. 2016 Aug 1;22(15):3755-63
pubmed: 26920887
Lancet Oncol. 2020 Nov;21(11):1455-1464
pubmed: 33152285
J Clin Oncol. 2016 Feb 20;34(6):542-9
pubmed: 26527775
Cancers (Basel). 2023 Mar 26;15(7):
pubmed: 37046648
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
JAMA Oncol. 2023 Apr 1;9(4):490-499
pubmed: 36602784
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Ann Oncol. 2021 Oct;32(10):1236-1244
pubmed: 34311075
Clin Cancer Res. 2022 Sep 1;28(17):3677-3685
pubmed: 35713517
Curr Top Microbiol Immunol. 2010;347:79-104
pubmed: 20582532
Annu Rev Med. 2015;66:111-28
pubmed: 25587647
Clin Breast Cancer. 2021 Feb;21(1):80-91.e7
pubmed: 33183970
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Clin Breast Cancer. 2023 Jun;23(4):350-362
pubmed: 37149421
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Clin Cancer Res. 2017 Jul 15;23(14):3529-3536
pubmed: 28053022
Oncologist. 2020 Dec;25(12):e1909-e1920
pubmed: 33000490
Cancer Res Treat. 2023 Apr;55(2):531-541
pubmed: 36097803
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Lancet Oncol. 2022 Mar;23(3):353-361
pubmed: 35085506
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36109084
Breast Cancer Res Treat. 2023 Jun;199(2):243-252
pubmed: 36944848
J Breast Cancer. 2018 Dec;21(4):382-390
pubmed: 30607159
Eur J Cancer. 2021 May;148:287-296
pubmed: 33765513
BMC Cancer. 2019 Oct 21;19(1):973
pubmed: 31638935
Lancet Oncol. 2014 May;15(6):640-7
pubmed: 24657003
Crit Rev Oncol Hematol. 2023 Apr;184:103952
pubmed: 36854373
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
JAMA Oncol. 2021 Jul 01;7(7):978-984
pubmed: 34014249
Cancers (Basel). 2022 Jan 21;14(3):
pubmed: 35158800
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
Nat Rev Drug Discov. 2023 Feb;22(2):101-126
pubmed: 36344672
Breast Cancer Res. 2020 May 13;22(1):45
pubmed: 32404150
J Clin Oncol. 2022 Sep 1;40(25):2946-2956
pubmed: 35763704